TEST:

PredicineCNB™

"This study compared the variation landscape between gastric and colon cancer patients, and demonstrated the technical feasibility of genome-wide copy number variations through liquid biopsy, revealing its potential clinical utility of longitudinal disease monitoring."

Finally, serial analysis of plasma cfDNA demonstrated an increase in ctDNA TF and cancer variants, preceding evidence of radiographic and clinical disease progression in many patients.Conclusion We conducted a comprehensive concordance study to infer cfDNA TF using PredicineWES+ and PredicineCNB in more than 300 patient samples. Our study demonstrated its clinical utility where the integrated TF analysis may provide a more robust and accurate estimation of disease burden in cancer patients.

We conducted a comprehensive clinical study using PredicineCNB in 1,000 patients with prostate and bladder cancers, demonstrating the promising clinical application of liquid biopsy-based genome-wide copy number changes in therapy monitoring.